Form 8-K - Current report:
SEC Accession No. 0001213900-24-052469
Filing Date
2024-06-13
Accepted
2024-06-13 16:35:33
Documents
14
Period of Report
2024-06-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207635-8k_onconetix.htm   iXBRL 8-K 28490
2 RELEASE AGREEMENT, DATED JUNE 10, 2024, BETWEEN THE COMPANY AND BRUCE HARMON ea020763501ex99-1_onconetix.htm EX-99.1 24833
  Complete submission text file 0001213900-24-052469.txt   237857

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20240608.xsd EX-101.SCH 3027
4 XBRL LABEL FILE onco-20240608_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE onco-20240608_pre.xml EX-101.PRE 22367
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0207635-8k_onconetix_htm.xml XML 3797
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 241041742
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)